Hypertension Management

Medication Dosage and Administration

The American Heart Association recommends considering an increase to telmisartan 80mg once daily if blood pressure control is inadequate after 2-4 weeks, while the American College of Cardiology recommends a starting dose of candesartan of 16 mg once daily, with titration to a target dose of 32 mg once daily for adults with hypertension and heart failure patients with reduced ejection fraction (HFrEF) 1, 2, 3
The European Society of Cardiology advises against combining telmisartan with another ACE inhibitor or ARB due to increased risk of renal dysfunction, hyperkalemia, and hypotension, and also notes that many physicians prescribe doses of candesartan that are too low (4-8 mg daily) for heart failure 2, 4
Elderly patients should start with lower doses and titrate more gradually, as recommended by the American Geriatrics Society, to minimize the risk of adverse effects 4

The target dose of candesartan for heart failure is 32 mg daily, with a minimum effective dose of at least 50% of the target dose (16 mg daily) and a titration schedule of adjusting the dose no more frequently than every 2 weeks 1
Underdosing is a common issue, with many physicians prescribing doses that are too low for heart failure, and failure to titrate to target doses due to concerns about hypotension or worsening renal function, despite evidence that higher doses provide greater clinical benefits 2
Permanent dose reductions are also a concern, as most dose reductions in clinical practice become permanent, whereas in clinical trials, 40% of patients who required temporary dose reduction were subsequently restored to target doses 2

Regular monitoring of renal function and electrolytes is crucial, with checks recommended within 1 week after initiation, and 1 and 4 weeks after increasing the dose, to minimize the risk of adverse effects and ensure optimal dosing 1, 2, 5
Blood pressure monitoring is also essential, with checks recommended within 2-4 weeks of initiating or changing the dose, to ensure that the patient is achieving the desired therapeutic effect 1, 6
When switching from an ACE inhibitor to an ARB, a 24-36 hour washout period is recommended to minimize the risk of adverse effects, as stated by the American Journal of Kidney Diseases, and renal function (serum creatinine, eGFR) and serum potassium should be checked before switching and monitored within 1-2 weeks of initiating the ARB 6, 7

The National Kidney Foundation advises using caution when switching to an ARB in patients with renal impairment (eGFR <30 mL/min/1.73m² or serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) 8
Candesartan should be used with caution in patients with bilateral renal artery stenosis, as recommended by the European Society of Cardiology, and avoided in patients treated with both an ACE inhibitor and an aldosterone antagonist 5
Patients are typically switched from an ACE inhibitor to an ARB due to ACE inhibitor-induced cough (occurs in up to 20% of patients) or angioedema (occurs in <1% of patients but more frequently in Black patients) 6, 9

Candesartan is indicated for patients with LVEF ≤40% with mild to severe symptoms (NYHA class II-IV), as recommended by the European Society of Cardiology, and the American College of Cardiology recommends a blood pressure goal of <130/80 mmHg for patients with hypertension 5, 10
Avoid routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist as this combination is potentially harmful, warns the American Heart Association, and the European Society of Cardiology recommends avoiding concurrent use with other ACE inhibitors or ARBs 5, 8

Candesartan has a similar side effect profile to ACE inhibitors, except for cough, as noted by the European Society of Cardiology, and the Circulation journal warns about the risk of hypotension, especially in volume-depleted patients, and the importance of monitoring potassium levels, as ARBs can cause hyperkalemia similar to ACE inhibitors 5, 6